GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders

Affiliations

• ¹ Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Baltimore, MD, USA. lorenzo.leggio@nih.gov.
• ² Bowles Center for Alcohol Studies and Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
• ³ Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Baltimore, MD, USA.
• ⁴ Psychiatric Centre Copenhagen, Mental Health Services in the Capitol Region of Denmark, Copenhagen, Denmark.
• ⁵ Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
• ⁶ Department of Psychiatry, University of Colorado School of Medicine, Aurora, CO, USA.
• ⁷ Department of Pharmacology & Physiology, Oklahoma State University Center for Health Sciences, Tulsa, OK, USA.
• ⁸ OSU Biomedical Imaging Center, Oklahoma State University Center for Health Sciences, Tulsa, OK, USA.